Tarsus Pharmaceuticals, Inc. (TARS)
| Market Cap | 2.64B |
| Revenue (ttm) | 451.36M |
| Net Income (ttm) | -66.42M |
| Shares Out | 42.56M |
| EPS (ttm) | -1.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 456,795 |
| Open | 62.63 |
| Previous Close | 60.93 |
| Day's Range | 61.64 - 63.33 |
| 52-Week Range | 38.51 - 85.25 |
| Beta | 0.63 |
| Analysts | Buy |
| Price Target | 89.00 (+43.54%) |
| Earnings Date | May 5, 2026 |
About TARS
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner ... [Read more]
Financial Performance
In 2025, Tarsus Pharmaceuticals's revenue was $451.36 million, an increase of 146.71% compared to the previous year's $182.95 million. Losses were -$66.42 million, -42.52% less than in 2024.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for TARS stock is "Buy." The 12-month stock price target is $89.0, which is an increase of 43.54% from the latest price.
News
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that the first participant has been dosed in the Phase 2 clinical trial (Calliope) evalua...
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory ap...
Tarsus Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
XDEMVY's launch has exceeded expectations, with rapid revenue growth, broad payer coverage, and strong prescriber engagement. The addressable market remains largely untapped, and DTC campaigns are expanding awareness. Peak sales guidance has doubled to $2B+, with a robust pipeline and strong financials supporting future growth.
Tarsus Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
The company is rapidly expanding in eye care, with XDEMVY achieving $450M in year-two revenue and targeting $2B+ peak sales. Pipeline assets TP-04 and TP-05 address large unmet needs, with key data readouts expected in 2027. DTC efforts and broad payer coverage are fueling growth.
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
Tarsus Pharmaceuticals Earnings Call Transcript: Q4 2025
Full-year 2025 net sales reached $451.4 million, with XDEMVY now profitable and US peak sales potential raised to over $2 billion. 2026 guidance projects 50%+ revenue growth, strong gross margins, and continued pipeline expansion, supported by robust prescriber and patient demand.
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutic...
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23, 2...
Tarsus Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Strong Q3 results and robust revenue guidance reflect effective commercial execution and DTC strategy. Pipeline progress includes a phase II ocular rosacea study starting by year-end and a Lyme disease prophylactic advancing toward partnership.
Tarsus Pharmaceuticals Earnings Call Transcript: Q3 2025
Q3 2025 saw exceptional growth, with XDEMVY achieving $119M in net sales and over 103,000 bottles dispensed, driven by strong physician adoption and DTC efforts. Guidance for Q4 and 2025 remains robust, with continued expansion in pipeline and international markets.
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
Delivered quarterly XDEMVY ® net sales of approximately $119 million, up approximately 147% year-over-year
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4, 2...
Tarsus Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
XDEMVY continues robust growth with strong prescriber engagement, high insurance coverage, and effective DTC campaigns. Expansion efforts focus on increasing prescribing depth, retreatment rates, and international markets, while pipeline assets in ocular rosacea and Lyme disease prevention advance toward clinical milestones.
Top 2 Health Care Stocks That May Fall Off A Cliff In August
As of Aug. 20, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Tarsus Pharmaceuticals Earnings Call Transcript: Q2 2025
Record Q2 net sales of $102.7M and 91,000 bottles dispensed highlight XDEMVY's rapid adoption, driven by DTC campaigns and broad access. Guidance calls for continued growth, with a robust pipeline and expanding prescriber base supporting long-term potential.
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY ® launch, an increase of 152% year over year
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, August 6, 2...
Tarsus Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference
XDEMVY's launch has driven strong sequential growth, aided by an expanded sales force and early payer coverage. Prescribing is broadening across multiple eye care categories, with significant market potential remaining. Pipeline programs in ocular rosacea and Lyme disease are advancing, and international expansion is underway.
Tarsus Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025
XDEMVY continues to drive strong revenue growth, with expanding adoption among eye care professionals and a robust sales force. Pipeline programs in ocular rosacea and Lyme disease offer significant future opportunities, while international expansion and business development are underway.
Tarsus Pharmaceuticals Transcript: 45th Annual William Blair Growth Stock Conference
XDEMVY's launch has exceeded expectations, driven by strong prescriber education, broad payer coverage, and expanding sales force efficiency. Growth is supported by direct-to-consumer campaigns and new market opportunities, with a robust pipeline targeting ocular rosacea and Lyme disease.
Tarsus Pharmaceuticals Transcript: Stifel 2025 Virtual Ophthalmology Forum
XDEMVY’s launch has driven strong demand, broad payer coverage, and rapid physician adoption, with a focus on expanding within a 9 million patient segment and deepening engagement among 15,000 key prescribers. Pipeline assets target ocular rosacea and Lyme disease, supported by robust financial resources.
Tarsus Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025
XDEMVY's launch has exceeded expectations, with strong sales, broad payer coverage, and ongoing market education driving growth. International expansion and a robust pipeline targeting ocular rosacea and Lyme disease are underway, supported by a strong cash position.
Tarsus Pharmaceuticals Transcript: BofA Securities 2025 Healthcare Conference
XDEMVY's launch has surpassed expectations, with strong revenue growth, broadening prescriber adoption, and over 90% payer coverage. Pipeline development continues with ocular rosacea and Lyme disease programs, while DTC and Salesforce expansion are set to drive further growth.
Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown
GREENFIELD, Ind. , May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEM...
Tarsus Pharmaceuticals Earnings Call Transcript: Q1 2025
Q1 2025 delivered $78M in XDEMVY sales, up 217% year-over-year, driven by expanded sales force, broad payer coverage, and impactful DTC campaigns. Strong financial position with $408M in cash supports continued growth and pipeline advancement.